Q32 Bio IncNASDAQ:QTTB
- LAST PRICE26.9100
- TODAY'S CHANGE (%)-0.0100 (-0.0371%)
- Bid / Lots20.0000/ 1
- Ask / Lots28.0600/ 1
- Open / Previous Close26.9200 / 26.9200
- Day Range
- 52 Week Range
- Volume31,887
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | QTTB |
|---|---|---|
| 09:32 ET | 641 | 26.92 |
| 09:35 ET | 143 | 26.9654 |
| 09:39 ET | 100 | 27.53 |
| 09:44 ET | 111 | 26.44 |
| 09:53 ET | 110 | 26.41 |
| 10:02 ET | 735 | 26.11 |
| 10:08 ET | 400 | 26.62 |
| 10:09 ET | 200 | 26.44 |
| 10:20 ET | 116 | 26.6563 |
| 10:22 ET | 400 | 26.45 |
| 10:27 ET | 200 | 26.44 |
| 10:29 ET | 300 | 26.255 |
| 10:33 ET | 100 | 26.44 |
| 10:42 ET | 400 | 26.15 |
| 11:21 ET | 200 | 26.15 |
| 11:48 ET | 600 | 26.04 |
| 11:50 ET | 100 | 26.04 |
| 11:57 ET | 1024 | 25.88 |
| 11:59 ET | 200 | 25.8 |
| 12:01 ET | 100 | 26.01 |
| 12:03 ET | 100 | 25.905 |
| 12:10 ET | 100 | 25.925 |
| 12:14 ET | 2000 | 26.09 |
| 12:19 ET | 1000 | 26.11 |
| 12:21 ET | 100 | 26.278 |
| 12:26 ET | 400 | 26.535 |
| 12:30 ET | 100 | 26.84 |
| 12:32 ET | 300 | 26.895 |
| 12:33 ET | 877 | 27.145 |
| 12:39 ET | 100 | 27.03 |
| 12:44 ET | 518 | 27.1238 |
| 12:48 ET | 100 | 27.13 |
| 12:50 ET | 100 | 27.13 |
| 12:53 ET | 600 | 27.17 |
| 01:00 ET | 4624 | 26.91 |
Nov 7, 2024
Press Release: Q32 Bio Reports Third Quarter 2024 Financial Results and Provides Corporate Update, from 6:59AM ET on Thursday Nov 07, 2024 by Dow Jones
6:59AM ET on Thursday Nov 07, 2024 by Dow JonesQ32 Bio Reports Third Quarter 2024 Financial Results and Provides Corporate Update, from 6:59AM ET on Thursday Nov 07, 2024 by Dow Jones
6:59AM ET on Thursday Nov 07, 2024 by Dow Jones
Nov 5, 2024
Q32 Bio to Participate in Guggenheim's Inaugural Healthcare Innovation Conference, from 6:59AM ET on Tuesday Nov 05, 2024 by Dow Jones
6:59AM ET on Tuesday Nov 05, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Q32 Bio Inc | 327.9M | -3.6x | --- |
Northwest Biotherapeutics Inc | 324.5M | -4.5x | --- |
Kodiak Sciences Inc | 344.7M | -1.8x | --- |
Compass Pathways PLC | 309.3M | -2.1x | --- |
Design Therapeutics Inc | 348.2M | -7.1x | --- |
Jasper Therapeutics Inc | 348.6M | -4.8x | --- |
Company Information
Q32 Bio Inc. is a clinical-stage biotechnology company. The Company is engaged in developing biologic therapeutics targeting potent regulators of the innate and adaptive immune systems to re-balance immunity in autoimmune and inflammatory diseases. Its lead programs, focused on the IL-7 / TSLP receptor pathways and complement system, address immune dysregulation to help patients take back control of their lives. Its program for adaptive immunity, bempikibart (ADX-914), is a fully human anti-IL-7Ra antibody that re-regulates adaptive immune function for the treatment of autoimmune diseases. It is being evaluated in two Phase II trials for the treatment of atopic dermatitis and alopecia areata. Its program for innate immunity, ADX-097, is based on a platform enabling tissue-targeted regulation of the complement system without long-term systemic blockade. The Company has completed a first-in-human, Phase I ascending dose clinical study of ADX-097 in healthy volunteers.
Contact Information
- Headquarters
- 830 Winter StreetWALTHAM, MA, United States 02451
- Phone
- 781-999-0232
- Fax
- 302-655-5049
Executives
- Independent Chairman of the Board
- Mark Iwicki
- President, Chief Financial Officer, Treasurer
- Lee Kalowski
- Chief Executive Officer, Company Secretary, Director
- Jodie Morrison
- Chief Scientific Officer and President of Research
- Shelia Violette
- Chief Medical Officer
- Jason Campagna
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $327.9M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 12.2M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | -0.44 |
EPS | $-7.44 |
Book Value | $22.64 |
P/E Ratio | -3.6x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
